^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
UCLM802
i
Other names: UCLM802, anti-MESO CAR T, mRNA CAR-mesothelin T Cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
UTC Therap
Drug class:
Mesothelin-targeted CAR-T immunotherapy
Related drugs:
1year
UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors (clinicaltrials.gov)
P1, N=87, Recruiting, Zhejiang University
New P1 trial
|
IL6 (Interleukin 6) • MSLN (Mesothelin) • IL10 (Interleukin 10)
|
cyclophosphamide • UCLM802
1year
MSLN-targeted CAR-T Cells in Solid Tumors. (clinicaltrials.gov)
P1, N=87, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
New P1 trial • CAR T-Cell Therapy • Metastases
|
IL6 (Interleukin 6) • MSLN (Mesothelin) • IL10 (Interleukin 10)
|
UCLM802
1year
UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors (clinicaltrials.gov)
P1, N=87, Not yet recruiting, Peking University
New P1 trial • CAR T-Cell Therapy • Metastases
|
IL6 (Interleukin 6) • MSLN (Mesothelin) • IL10 (Interleukin 10)
|
cyclophosphamide • UCLM802
1year
Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors (clinicaltrials.gov)
P1, N=0, Withdrawn, Shanghai Pudong Hospital | N=20 --> 0 | Recruiting --> Withdrawn
Enrollment change • Trial withdrawal • CAR T-Cell Therapy • Metastases
|
MSLN (Mesothelin)
|
cyclophosphamide • fludarabine IV • UCLM802
over1year
Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors (clinicaltrials.gov)
P1, N=20, Recruiting, Shanghai Pudong Hospital
New P1 trial • CAR T-Cell Therapy
|
MSLN (Mesothelin)
|
cyclophosphamide • fludarabine IV • UCLM802
Share via
